Develops cancer drugs that stimulate the immune system.
Jun 2026Revenue $4.70M/yrExpenses $35.5M/yr
No trendCash runway ≈ 7 months from Jun 2026
Figures by year
When will Bolt Biotherapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.70M and expenses $35.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $7.70M | $43.8M | −$36.1M |
| Dec 2024 | $7.69M | $80.7M | −$73.0M |
| Dec 2023 | $7.88M | $84.1M | −$76.2M |
| Dec 2022 | $5.73M | $96.0M | −$90.3M |
| Dec 2021 | $1.26M | $94.0M | −$92.8M |
| Dec 2020 | $231K | $49.4M | −$49.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.